SE0203817D0 - New composition - Google Patents

New composition

Info

Publication number
SE0203817D0
SE0203817D0 SE0203817A SE0203817A SE0203817D0 SE 0203817 D0 SE0203817 D0 SE 0203817D0 SE 0203817 A SE0203817 A SE 0203817A SE 0203817 A SE0203817 A SE 0203817A SE 0203817 D0 SE0203817 D0 SE 0203817D0
Authority
SE
Sweden
Prior art keywords
nitrate
new composition
active substance
pharmaceutically active
administration
Prior art date
Application number
SE0203817A
Other languages
Swedish (sv)
Inventor
Jon Lundberg
Eddie Weitzberg
Original Assignee
Jon Lundberg
Eddie Weitzberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jon Lundberg, Eddie Weitzberg filed Critical Jon Lundberg
Priority to SE0203817A priority Critical patent/SE0203817D0/en
Publication of SE0203817D0 publication Critical patent/SE0203817D0/en
Priority to AU2003291600A priority patent/AU2003291600A1/en
Priority to PCT/SE2003/002052 priority patent/WO2004056376A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

The use of nitrate (NO3-) in pharmaceutical formulations, e.g. in combination with a pharmaceutically active substance has been found to prevent or alleviate known side effects, as well as enhance the effect of many pharmaceutically active substances without the need for modification of the active substance itself. The invention also presents methods of treatment, based on the administration of nitrate.
SE0203817A 2002-12-20 2002-12-20 New composition SE0203817D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0203817A SE0203817D0 (en) 2002-12-20 2002-12-20 New composition
AU2003291600A AU2003291600A1 (en) 2002-12-20 2003-12-19 Pharmaceutical formulations containing nitrate
PCT/SE2003/002052 WO2004056376A1 (en) 2002-12-20 2003-12-19 Pharmaceutical formulations containing nitrate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203817A SE0203817D0 (en) 2002-12-20 2002-12-20 New composition

Publications (1)

Publication Number Publication Date
SE0203817D0 true SE0203817D0 (en) 2002-12-20

Family

ID=20289966

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203817A SE0203817D0 (en) 2002-12-20 2002-12-20 New composition

Country Status (3)

Country Link
AU (1) AU2003291600A1 (en)
SE (1) SE0203817D0 (en)
WO (1) WO2004056376A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835555B2 (en) 2007-02-26 2020-11-17 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
CA2678097C (en) 2007-02-26 2023-03-14 Jon Lundberg New use of nitrites and nitrates and compositions containing these
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
ES2618655T3 (en) 2007-02-26 2017-06-21 Heartbeet Ltd. Composition that improves its performance and use

Also Published As

Publication number Publication date
AU2003291600A1 (en) 2004-07-14
WO2004056376A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
NO20062504L (en) Compositions and dosage forms for improved absorption
BR0312573A (en) Phenyl- [4- (3-phenyl-1h-pyrazol-4-yl) -pyrimidin-2-yl] -amine derivatives
CY1118179T1 (en) PHARMACEUTICAL COMPOSITION
BG66093B1 (en) Controlled release compositions comprising nimesulide
BR0214343A (en) 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1
DK1781277T3 (en) Combination composition comprising Ibuprofen and Paracetamol
DE60334773D1 (en) FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
TW200510375A (en) New compounds
MY143795A (en) Tetrahydropyridoindole derivatives
ATE401874T1 (en) ADMINISTRATION OF CAPSAICINOIDS
DE602005021770D1 (en) INDOLE-1-YL-ACETIC DERIVATIVES
CY1111458T1 (en) DOSAGE FORMS OF GENERAL LINEAR, ANAVARASUS, ORAL FENTANYL AND METHODS OF ADMINISTRATION
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
DK1654253T3 (en) Substituted 3-pyrrolidine indole derivatives
NO20061236L (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hoziiton
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
EA200501821A1 (en) PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION
SE0203817D0 (en) New composition
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
SE0000303D0 (en) Novel compounds
ATE451340T1 (en) DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DK1273301T3 (en) Pharmaceuticals based on active ingredients that can be used for illicit administration
EA200601015A1 (en) ORAL COMPOSITIONS OF DEOXYPEGANINE AND THEIR APPLICATION
DE60312642D1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE